Galectin Therapeutics (GALT) Competitors $5.30 +0.21 (+4.13%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$5.17 -0.13 (-2.45%) As of 10/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. ELVN, TRVI, WVE, ORIC, SNDX, TRML, NBTX, MAZE, ARDX, and CVACShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Enliven Therapeutics (ELVN), Trevi Therapeutics (TRVI), WAVE Life Sciences (WVE), Oric Pharmaceuticals (ORIC), Syndax Pharmaceuticals (SNDX), Tourmaline Bio (TRML), Nanobiotix (NBTX), Maze Therapeutics (MAZE), Ardelyx (ARDX), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Enliven Therapeutics Trevi Therapeutics WAVE Life Sciences Oric Pharmaceuticals Syndax Pharmaceuticals Tourmaline Bio Nanobiotix Maze Therapeutics Ardelyx CureVac Galectin Therapeutics (NASDAQ:GALT) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Does the media prefer GALT or ELVN? In the previous week, Enliven Therapeutics had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Enliven Therapeutics and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.56 beat Enliven Therapeutics' score of 0.16 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, GALT or ELVN? Galectin Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Which has higher valuation & earnings, GALT or ELVN? Enliven Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$47.05M-$0.64-8.28Enliven TherapeuticsN/AN/A-$89.02M-$2.00-10.60 Is GALT or ELVN more profitable? Galectin Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -225.32% Enliven Therapeutics N/A -29.15%-27.88% Do analysts recommend GALT or ELVN? Galectin Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 13.21%. Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 94.43%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Enliven Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders hold more shares of GALT or ELVN? 11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryGalectin Therapeutics and Enliven Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$326.07M$3.01B$6.22B$10.68BDividend YieldN/A57.76%5.72%4.88%P/E Ratio-8.2823.5929.1427.22Price / SalesN/A759.39582.41131.48Price / CashN/A171.3937.5161.65Price / Book-3.155.4112.476.59Net Income-$47.05M$33.06M$3.32B$276.14M7 Day Performance2.12%-0.68%0.79%-0.72%1 Month Performance7.72%8.13%7.32%2.47%1 Year Performance102.29%-2.15%63.84%33.90% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.075 of 5 stars$5.30+4.1%$6.00+13.2%+101.5%$326.07MN/A-8.289ELVNEnliven Therapeutics2.0934 of 5 stars$22.12+3.3%$41.20+86.3%-26.6%$1.27BN/A-11.0650Insider TradeTRVITrevi Therapeutics2.6767 of 5 stars$10.69+3.2%$21.75+103.5%+217.9%$1.26BN/A-25.4520Gap DownWVEWAVE Life Sciences4.7402 of 5 stars$7.81flat$20.57+163.4%-48.0%$1.24B$108.30M-8.68240Analyst ForecastORICOric Pharmaceuticals4.3555 of 5 stars$12.38-3.1%$17.29+39.6%+38.2%$1.24BN/A-6.5580Positive NewsSNDXSyndax Pharmaceuticals4.0769 of 5 stars$15.57+8.9%$38.00+144.1%-22.2%$1.23B$23.68M-4.00110Positive NewsAnalyst RevisionHigh Trading VolumeTRMLTourmaline Bio1.6025 of 5 stars$47.93+0.1%$45.65-4.8%+69.3%$1.23BN/A-13.9744Positive NewsShort Interest ↓High Trading VolumeNBTXNanobiotix0.8504 of 5 stars$24.52-4.2%$11.00-55.1%+370.3%$1.23B$39.18M0.00100Gap DownMAZEMaze Therapeutics2.5916 of 5 stars$29.75+7.0%$33.83+13.7%N/A$1.22B$167.50M0.00121Short Interest ↑ARDXArdelyx4.2919 of 5 stars$5.10+1.4%$11.70+129.4%-10.0%$1.21B$333.61M-22.1790CVACCureVac3.5145 of 5 stars$5.36flat$6.83+27.5%+93.9%$1.20B$579.18M5.58880 Related Companies and Tools Related Companies ELVN Alternatives TRVI Alternatives WVE Alternatives ORIC Alternatives SNDX Alternatives TRML Alternatives NBTX Alternatives MAZE Alternatives ARDX Alternatives CVAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredThe Republican party is falling apartSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
